We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 899

Nautilus standard sinks Dow patents
  • Foley & Lardner LLP
  • USA
  • August 31 2015

Dow Chemical Company ("Dow") lost a ruling that competitor NOVA Chemical Corporation and NOVA Chemicals Inc. (collectively "NOVA") infringed claims


FDA’s proposed naming convention for biologics
  • Foley & Lardner LLP
  • USA
  • August 28 2015

On August 27, 2015, the Food and Drug Administration (FDA) released draft guidance on nonproprietary naming of biological products. The agency's


Amgen and Apotex do the biosimilar patent dance
  • Foley & Lardner LLP
  • USA
  • August 27 2015

Amgen has filed a complaint under the Biologics Price Competition and Innovation Act (BPCIA), asserting that a biosimilar application filed by Apotex


Will the TELE-MED Act of 2015 really change licensure rules?
  • Foley & Lardner LLP
  • USA
  • August 26 2015

Congress is reviewing legislation designed to permit telemedicine providers to treat Medicare patients across state lines without the need for


Kyle Bass loses round 1 of IPR attack against pharmabiotech patents
  • Foley & Lardner LLP
  • USA
  • August 26 2015

On August 24, 2015, the Patent Trial and Appeal Board (PTAB) declined institution of two petitions filed by Coalition For Affordable Drugs for Inter


PTAB denies institution of Kyle Bass's Ampyra patent challenge
  • Foley & Lardner LLP
  • USA
  • August 25 2015

The USPTO Patent Trial and Appeal Board (PTAB) has put an end to Kyle Bass's Ampyra patent challenge, by denying institution of Inter Partes Review


AmerisourceBergen guest post: solutions to overcome reimbursement challenges in personalized medicine
  • Foley & Lardner LLP
  • USA
  • August 25 2015

The continued development and refinement of personalized medicine (PM) has offered an opportunity to revolutionize medical practice and improve


Protecting diagnostic innovation two actor infringement liability
  • Foley & Lardner LLP
  • USA
  • August 24 2015

In Akamai Techs. Inc. v. Limelight Networks, Inc., (August 13, 2015 Fed. Cir.) an en banc Federal Circuit unanimously held that direct infringement


Sequenom seeks rehearing en banc
  • Foley & Lardner LLP
  • USA
  • August 18 2015

Sequenom, Inc. has filed a petition for rehearing en banc of the Federal Circuit decision that held its diagnostic method claims invalid under 35 USC


Another delay for the two-midnight rule
  • Foley & Lardner LLP
  • USA
  • August 18 2015

The Centers for Medicare and Medicaid Services (CMS) announced, on August 12, 2015, that it has extended the enforcement delay of the controversial